替尔泊肽转换司美格鲁肽，将进一步改善减重降糖疗效？

Core Viewpoint - The article discusses the potential benefits of switching from GLP-1 receptor agonists (such as Semaglutide and Dulaglutide) to the GIP/GLP-1 receptor agonist Tirzepatide for better blood sugar control and weight loss in type 2 diabetes patients [7][6]. Group 1: Research Findings - A model was developed to predict the effects of different treatment regimens on blood sugar control and weight loss based on clinical trial data [5]. - The model predicts that switching to Tirzepatide after using Semaglutide or Dulaglutide can lead to further reductions in HbA1c levels and weight loss [6]. - After 66 weeks of switching to Tirzepatide, HbA1c levels are expected to decrease by 1.95% to 2.46%, with weight loss ranging from 6.50 kg to 12.10 kg [6]. Group 2: Comparison of Drugs - Semaglutide and Tirzepatide are both designed for weekly administration, with Semaglutide having a half-life of approximately 165-184 hours and Tirzepatide having a half-life of 116.7 hours [9]. - Tirzepatide, being a dual-target agonist, shows superior weight loss effects compared to Semaglutide [10]. - Semaglutide has drawbacks, including potential weight regain after discontinuation, with patients possibly regaining two-thirds of lost weight within a year [10]. Group 3: Market Dynamics - The GLP-1 market is highly competitive, with major players like Eli Lilly and Novo Nordisk expected to dominate the obesity drug market, potentially capturing 80% of the market share by 2030 [12]. - New combination therapies, such as CagriSema, which combines Semaglutide and Cagrilintide, are being developed to enhance weight loss and blood sugar control [11][12].